CX-5461 has shown efficacy in combination with other therapies targeting ribosome biogenesis in a number of MYC-driven cancer models.290,293 PIM kinase is co-elevated in MYC-driven prostate cancer303 and is responsible for increasing MYC transcriptional activity and stability, and increasing translational activity via stimulation of phosphorylation of 4E-BP1. The gene discussed is MYC; the disease is urogenital neoplasm.